Posters

      Cigarette Mainstream Smoke Affects Arterial Thrombosis and Vessel Remodeling after Vascular Injury in Apolipoprotein E-Deficient Mice

      Wallerath, T.; Schroeter, M.; Meurrens, K.; Lebrun, S.; Konstantinides, S.; Schleef, R.; Schäfer, K.

      Conference date
      Mar 13, 2007
      Conference name
      German Society for Experimental and Clinical Pharmacology and Toxicology 
      Link to more information
      Topic
      Summary

      Cardiovascular disease and its thrombotic complications, particularly myocardial infarction and stroke, are a main cause of death in industrialized countries. Currently, little is known about the underlying pathomechanisms of cigarette smoke on thrombosis and subsequent vessel wall remodeling, partly due to a lack of adequate in vivo models. We investigated the biological effects of sub-chronic inhalation exposure to cigarette mainstream smoke (MS) from the University of Kentucky reference cigarette 2R4F at doses of 600, 1200, 1800, and 2400 µg total particulate matter per liter per day on arterial thrombosis and intimal hyperplasia using the ferric chloride model of vascular injury in male apolipoprotein e-deficient (ApoE-/-) mice. Arterial thrombosis was analyzed in the left carotid artery by determining the time to thrombotic occlusion and patency rate after vascular injury. A dose-dependent decrease was seen in median time to occlusion (14.9 min for control, 9.7 min for MS-1800, and 8.0 min for MS-2400; p < 0.001 compared to control) and lower vascular patency rates after 25 minutes (40% for control, 10% for MS-1800, and 0% for MS-2400; p < 0.001 compared to control). Three weeks later, intimal hyperplasia was analyzed using immunohistochemistry and morphometry. Immunohistochemistry of neointimal lesions revealed an MS exposure-associated increase in the amount of alpha-actin-positive smooth muscle cells (range: 16% (control) to 25% (MS-2400); p < 0.05 for MS-2400 compared to control). No differences were seen in the number of apoptotic cells. Morphometry revealed an MS exposure-associated increase intima-media ratio (p < 0.05 for MS-1800 compared to control and p < 0.01 for MS-2400 compared to control). These data indicate that subchronic exposure of ApoE-/- mice to MS promotes arterial thrombosis and modulates the size and composition of vascular lesions.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.